This website is intended for healthcare professionals only

Comprehensive Anatomical Render Of Breast Cancer In A Human Female

Where are we now: Clinical utility and challenges of circulating tumor DNA in breast cancer

Saumya Easaw, Antoinette R Tan, Arielle L Heeke

Circulating tumor DNA (ctDNA) has emerged as an innovative and minimally invasive tool in precision oncology. With a short half-life of 30–120 min, ctDNA provides real-time insight into tumor dynamics.1 In early-stage breast cancer, there is growing evidence supporting its potential for minimal residual disease (MRD) detection and recurrence monitoring. In metastatic breast cancer (MBC), ctDNA […]

touchREVIEWS in Oncology & Haematology. 2026;22(2):1–4:Online ahead of journal publication

Hematology

IACH 2019: Welcome

Published Online: Feb 27th 2020

International Academy for Clinical Hematology IACH

Prof. Mohamad Mohty

The 2nd Annual Meeting of the IACH September 19-21, 2019 | Paris, France

Published online: 27 February 2020

ZUMA-23 study of axicabtagene ciloleucel as first-line therapy in large B-cell lymphoma: Jason Westin, EHA 2023

ZUMA-23 (NCT05605899) is an on-going phase 3 study investigating axicabtagene ciloleucel (axi-cel) CAR T cell therapy as a first-line therapy in patients with high-risk large B-cell lymphoma. touchONCOLOGY caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss what previous clinical trials have taught us about […]

Related Videos in Hematology

Developed by Touch

Axicabtagene ciloleucel for the treatment of large B-cell lymphoma: Jason Westin, EHA 2023

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved to treat patients with relapsed/refractory large B-cell lymphoma. We caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, ...

Developed by Touch

Bernd Jilma, ASH 2022: Pegcetacoplan in patients with cold agglutinin disease, the CASCADE phase III trial

The CASCADE trial aims to assess the efficacy and safety of pegcetacoplan in patients with cold agglutinin disease (CAD). In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the CASCADE trial ...

Developed by Touch

Bernd Jilma, ASH 2022: The pathophysiology and unmet treatment needs in cold agglutinin disease

Cold agglutinin disease (CAD) is a rare, autoimmune, clonal B cell disorder. In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the pathophysiology of CAD and the unmet treatment needs in ...

Developed by Touch

Srdan Verstovsek, ASH 2022: Momelotinib long-term safety in myelofibrosis disease - Analysis of SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials

Momelotinib, an oral JAK1/JAK2/ACVR1 inhibitor, was evaluated in 3 randomised controlled trials - SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM, in patients with high- and intermediate-risk myelofibrosis. In this touchONCOLOGY interview, we speak with Prof. Srdan Verstovsek (MD Anderson Cancer Center, Houston, ...

Developed by Touch

Saskia Middeldorp, ASH 2022: The efficacy of low-molecular-weight heparin in women with recurrent miscarriage and inherited thrombophilia - the ALIFE 2 trial

Studies have linked recurrent miscarriage with inherited thrombophilia. The ALIFE 2 trial aimed to assess the efficacy of low-molecular-weight heparin (LMWH) therapy in women with recurrent miscarriage and inherited thrombophilia. In this touchONCOLOGY interview, we speak with Professor Saskia Middeldorp (Radboud ...

Developed by Touch

Spero R Cataland, Rare Disease Day 2022: Acquired thrombotic thrombocytopenic purpura - Risks, complications and the impact on daily life

Dr Spero R Cataland (The Ohio State University, Wexner Medical Centre, Columbus, OH, USA) joins us for Rare Disease Day to discuss the importance of rapid diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood disorder in which blood ...

Steven Pipe, ASH 2020 – First Results from the HOPE-B Gene Therapy Trial

We had the pleasure to talk to Steven Pipe (University of Michigan, Ann Arbor, MI, USA) to discuss the use of gene therapy for the treatment of haemophilia B. The abstract 'First Data from the Phase 3 HOPE-B Gene Therapy Trial: ...

Efstathios Kastritis, EHA 2020: CYBORD in Amyloidosis and The ANDROMEDA Study

touchONCOLOGY joins Dr Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at EHA25 Virtual to discuss the ANDROMEDA study (NCT03201965), and the efficacy and safety of daratumumab in combination with CYBORD ...

George Goshua, EHA 2020: Endotheliopathy is Essential in COVID-19 Associated Coagulopathy

Dr George Goshua (Yale University School of Medicine, New Haven, CT, USA) shares with us his insights into the role of endotheliopathy in the development of coagulopathy in patients with COVID-19. Questions: 1. How common is coagulopathy in COVID-19 infection and ...

The 1st Online Master class in Transplantation and Hematology (MATH) by IACH

The International Academy for Clinical Hematology (IACH) welcomes you to attend the 1st Online Master class in Transplantation and Hematology (MATH) Saturday, June 6, 2020 For more information, click here.

The 3rd Annual Meeting of the International Academy: Focus on Leukemia

The 3rd Annual Meeting of the International Academy for Clinical Hematology (IACH): Focus on Leukemia October 1-3, 2020 Nice, France. Published Online: 24 February 2020...

TPO agents beyond ITP: aplastic anemia, inherited thrombocytopenia and chemotherapy induced thrombocytopenia

Speaker Prof. James Bussel Learning objectives - Understand that thrombopoietic agents (TPO) impacts the stem cell and thus can have trilineage effects - Recognize that TPO agents are an important way to increase the platelet count in patients with inherited ...

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Keep track of your clinical interests and newsletter subscriptions.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Already have an Account?

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

Register now for FREE access

Already registered? Login below.

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Learning Activities

Congress Highlights

Journals

Specialities

Where are we now: Clinical utility and challenges of circulating tumor DNA in breast cancer

Learning Activities

Congress Highlights

Journals

Specialities

Where are we now: Clinical utility and challenges of circulating tumor DNA in breast cancer

IACH 2019: Welcome

Register now for
FREE access

ZUMA-23 study of axicabtagene ciloleucel as first-line therapy in large B-cell lymphoma: Jason Westin, EHA 2023

Axicabtagene ciloleucel for the treatment of large B-cell lymphoma: Jason Westin, EHA 2023

Bernd Jilma, ASH 2022: Pegcetacoplan in patients with cold agglutinin disease, the CASCADE phase III trial

Bernd Jilma, ASH 2022: The pathophysiology and unmet treatment needs in cold agglutinin disease

Srdan Verstovsek, ASH 2022: Momelotinib long-term safety in myelofibrosis disease - Analysis of SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials

Saskia Middeldorp, ASH 2022: The efficacy of low-molecular-weight heparin in women with recurrent miscarriage and inherited thrombophilia - the ALIFE 2 trial

Spero R Cataland, Rare Disease Day 2022: Acquired thrombotic thrombocytopenic purpura - Risks, complications and the impact on daily life

Steven Pipe, ASH 2020 – First Results from the HOPE-B Gene Therapy Trial

Efstathios Kastritis, EHA 2020: CYBORD in Amyloidosis and The ANDROMEDA Study

George Goshua, EHA 2020: Endotheliopathy is Essential in COVID-19 Associated Coagulopathy

The 1st Online Master class in Transplantation and Hematology (MATH) by IACH

The 3rd Annual Meeting of the International Academy: Focus on Leukemia

TPO agents beyond ITP: aplastic anemia, inherited thrombocytopenia and chemotherapy induced thrombocytopenia

Latest articles videos and clinical updates - straight to your inbox

Connect With Us

Useful Links

In Partnership With

Specialities

Sign Up for Free Access to the Latest Clinical Updates in Your Specialty!

Learning Activities

Congress Highlights

Journals

Specialities

Congress Highlights

Trending Topic

Connect With Us:

IACH 2019: Welcome

Register now forFREE access

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Register now for FREE Access

Sign up with an Email

Register now for FREE access

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Register now for
FREE access